COVID-19 and diabetes: health risks
https://doi.org/10.30629/0023-2149-2024-102-3-252-256
Abstract
During the COVID-19 pandemic, many familiar processes had to be adapted due to various restrictions and high workload on healthcare workers. In particular, to reduce the risk of coronavirus infection, remote patient care technologies have been used more frequently. This study aims to analyze the impact of the COVID-19 pandemic and related restrictions on access to free educational courses on diabetes, disease dynamics, and patient awareness of necessary treatment methods. Changes in patient satisfaction with online learning compared to traditional face-to-face formats were studied, as well as changes in medication adherence with regular education and consultations. The authors described possible reasons for changes in the effectiveness of education and proposed measures to optimize treatment processes and patient information in Russia. The study showed that the COVID-19 pandemic led to a decrease in patient participation in educational programs on diabetes. This could have been due to fear of infection, lack of awareness of such programs, and socio-economic inequality.
About the Authors
E. S. Sokolova
Academician E.A. Wagner Perm State Medical University of the Ministry of Healthcare of Russia
Russian Federation
Russian Federation
Elizaveta S. Sokolova — Specialist, Resident
Perm
M. A. Palamarenko
Academician E.A. Wagner Perm State Medical University of the Ministry of Healthcare of Russia
Russian Federation
Russian Federation
Mariya A. Palamarenko
Perm
A. A. Osipov
Stavropol State Medical University of the Ministry of Healthcare of Russi
Russian Federation
Russian Federation
Andrey A. Osipov — Specialist, Resident
Stavropol
A. M. Chaulin
Samara Regional Clinical Cardiology Dispensary
Russian Federation
Russian Federation
Aleksey M. Chaulin — Dr of Sci. (Med.), Research Associate
Samara
E. V. Eliseeva
Academician E.A. Wagner Perm State Medical University of the Ministry of Healthcare of Russia
Russian Federation
Russian Federation
Evgeniya V. Eliseeva — Specialist, Resident
Perm
E. S. Koryakin
Academician E.A. Wagner Perm State Medical University of the Ministry of Healthcare of Russia
Russian Federation
Russian Federation
Egor S. Koryakin — Specialist, Resident
Perm
References
1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) What is diabetes? Diabetes Overview. 2016.
2. Howard-Thompson A. et al. Type 2 diabetes mellitus: outpatient insulin management. American Family Physician. 2018;97(1):29– 37. DOI: 10.13655/1.6.1234567
3. Roglic G. Diabetes. World Health Organization (WHO). 2022.
4. Dedov I.I., Kontsevaya A.V., Shestakova M.V., Belousov Yu.B., Balanova Yu.A., Khudyakov M.B., Karpov O.I. Economic burden of type 2 diabetes and its major cardiovascular complications in the Russian Federation. Sakharnyy diabet. 2016;19(6):518–526. (In Russian). DOI: 10.13655/1.6.1234567
5. Popovich L.D., Shestakova M.V., Potapchik E.G., Mayorov A.Yu., Vikulova O.K. Is it beneficial for the state to provide diabetic patients on insulin therapy with self-monitoring blood glucose devices according to regulatory needs? Sakharnyy diabet. 2017;20(2):108–118. (In Russian). DOI: 10.13655/1.6.1234567
6. An J. et al. Prevalence and incidence of microvascular and macro vascular complications over 15 years among patients with incident type 2 diabetes. BMJ Open Diabetes Research and Care. 2021;9(1):1–10. DOI: 10.13655/1.6.1234567
7. Glushchenko V .A ., Irklyenko E .K. Cardiovascular disease — one of the most important healthcare problems. Meditsina i organizatsiya zdra vo okhraneniya. 2019;4(1):56–63. (In Russian). DOI: 10.13655/1.6.1234567
8. Cardoso R. et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. Clinical Medicine. 2021;36:100933. DOI: 10.13655/1.6.1234567
9. Gerstein H.C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. New England Journal of Medicine. 2021;385(10):896–907. DOI: 10.13655/1.6.1234567
10. American Heart Association (AHA) Living healthy with diabetes. 2021.
11. Diabetes Prevention Program Research Group et al. Long-term eff ects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. The Lancet Diabetes & Endocrinology. 2015;3(11):866–875. DOI: 10.13655/1.6.1234567
12. Association of Diabetes Care and Education Specialists (ADCES). How diabetes education helps patients. 2021.
13. Rochmah N. et al. Quality of life differences in pre- and posteducational treatment in type 1 diabetes mellitus during COVID-19. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2021;14:2905–2911. DOI: 10.13655/1.6.1234567
14. Ascension Stories. A faith-based healthcare organization. [Electronic resource]. URL: https://healthcare.ascension.org/ (Access date 30.12.2022)
15. Gurdeep S. et al. Diabetes education and the COVID-19 pandemic. J. Endocrinol 2022;6(1):000172.
16. Hill-Briggs F. et al. Social determinants of health and diabetes: a scientifi c review. Diabetes care. 2021;44(1):258–279. DOI: 10.13655/1.6.1234567
17. Siminerio L.M. et al. The National Diabetes Education Program at 20 years: lessons learned and plans for the future. Diabetes care. 2018;41(2):209–218. DOI: 10.13655/1.6.1234567
18. Quinn L.M. et al. Use of MyDesmond digital education programme to support self-management in people with type 2 diabetes during the COVID-19 pandemic. Diabetic Medicine. 2021;38(3). DOI: 10.13655/1.6.1234567
19. Hartmann-Boyce J. et al. Diabetes and COVID-19: risks, mana gement, and learnings from other national disasters. Diabetes care. 2020;43(8):1695–1703. DOI: 10.13655/1.6.1234567
20. Zhang Z., Monro J., Venn B.J. Development and evaluation of an internet-based diabetes nutrition education resource. Nutrients. 2019;11(6):1217. DOI: 10.13655/1.6.1234567
Review
For citations:
Sokolova E.S., Palamarenko M.A., Osipov A.A., Chaulin A.M., Eliseeva E.V., Koryakin E.S. COVID-19 and diabetes: health risks. Clinical Medicine (Russian Journal). 2024;102(3):252-256. (In Russ.) https://doi.org/10.30629/0023-2149-2024-102-3-252-256
Views:
388
Email this article 